Stem Cell Transplant Associated With Better PFS in Natural Killer/T-Cell Lymphoma Edited by Katie Lennon July 24, 2026 Am J Hematol. 2026; doi:10.1002/ajh.70415

https://www.medscape.com/viewarticle/stem-cell-transplant-associated-better-pfs-natural-killer-t-2026a1000p7b?src= Upfront autologous stem cell transplantation (ASCT) consolidation is associated with improved progression-free survival (PFS) in patients with advanced-stage extranodal natural killer/T-cell lymphoma (NKTCL) who achieve a first complete remission after frontline therapy. Among 107 patients studied, those receiving ASCT had a 3-year PFS rate of 78.2% compared with 54.6% in the non-ASCT group.